Privacy Policy
Signals Blog

Contributors

Categories

The Canadian regulatory system for cell and gene therapies

Aileen J. Zhou brings over a decade of experience in biotech and medical device regulatory affairs. She is an active member and contributing author of the Regulatory Affairs Professional Society (RAPS) and Alliance for Regenerative Medicine’s Regulatory and CMC...

A foray into the future: Predictions for the year 2050

In part 1 of this feature marking the 10-year anniversary of Signals, we got to know the people behind the posts a little better. Now, we’re looking to the future of regenerative medicine and science with the help of our contributors. In this post, bloggers Lyla...

Comparing two snapshots of RM taken a decade apart

When Signals first burst onto the scene in 2012, the potential of the regenerative medicine industry still hadn’t set in for many. When the Alliance for Regenerative Medicine (ARM) published its first state of the industry report in 2012, the ARM chairman at the time,...